HGR4113 is a novel compound that was discovered by Glaceum Inc. through a Quantitative Structure-Activity Relationship (QSAR) study on Glabridin and its derivatives. HGR4113 showed competitive antihyperglycemic effects in db/db mice without any adverse event of obesity. The test consisted of a vehicle control group (db/db mice), a test group (HGR4113 150mg/kg), and two positive control groups (Metformin 300mg/kg and Pioglitazone 75mg/kg). HGR4113 was given orally once daily for 7 days for 8 consecutive weeks (qd×7×8). During the course of this study, HGR4113 exhibited a level of efficacy highly comparable to Pioglitazone, one of the oral antihyperglycemic agents available. More importantly, however, HGR4113 demonstrated weight maintenance effects similar to Metformin in db/db mice, whereas Pioglitazone caused db/db mice to develop significant signs of obesity as a critical adverse effect.

In conclusion, our test results suggest HGR4113 as a safe and effective drug for T2DM along with further clinical development.

Disclosure

K. Kim: None. S. Yoo: Employee; Self; Glaceum. I. Jo: Employee; Self; Glaceum Incoporation. K. Lim: Employee; Self; Glaceum Inc..

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.